Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney

Journal of the American College of Cardiology

Volumn 70, Issue 17, 2017, Pages 2139-2153

  Polhemus, David J ^a   Trivedi, Rishi K ^a   Gao, Juan ^a   Li, Zhen ^a   Scarborough, Amy L ^a   Goodchild, Traci T ^a   Varner, Kurt J ^a   Xia, Huijing ^a   Smart, Frank W ^a   Kapusta, Daniel R ^a   Lefer, David J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

fibrosis; heart failure; renal denervation; sympathetic nervous system; vascular function

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA 1; CONNECTIVE TISSUE GROWTH FACTOR; INTERLEUKIN 6; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; NORADRENALIN; SACUBITRIL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AMINOBUTYRIC ACID DERIVATIVE; NITRITE; RENIN; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; KIDNEY DENERVATION; KIDNEY NERVE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC NERVE; VASODILATATION; WISTAR KYOTO RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; CARDIAC MUSCLE; CHEMISTRY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; INNERVATION; KIDNEY; KIDNEY ARTERY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY; SYMPATHECTOMY;

AMINOBUTYRATES; ANGIOTENSIN II; ANIMALS; BISOPROLOL; BLOOD PRESSURE; ECHOCARDIOGRAPHY; HEART FAILURE; KIDNEY; MYOCARDIUM; NEPRILYSIN; NITRITES; NOREPINEPHRINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENAL ARTERY; RENIN; REPERFUSION INJURY; SYMPATHECTOMY; TETRAZOLES; VENTRICULAR FUNCTION, LEFT;

EID: 85032141151     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.08.056     Document Type: Article

References (43)

1. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
2. Watson, A.M., Hood, S.G., May, C.N., Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol 33 (2006), 1269–1274.
3. Brouri, F., Hanoun, N., Mediani, O., Saurini, F., Hamon, M., Vanhoutee, P.M., Lechat, P., Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol 485 (2004), 227–234.
4. Packer, M., Bristow, M.R., Cohn, J.N., et al., for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996), 1349–1355.
5. Garg, R., Yusuf, S., for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995), 1450–1456.
6. Flather, M.D., Yusuf, S., Kober, L., et al., for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000), 1575–1581.
7. McMurray, J.J., Ostergren, J., Swedberg, K., et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003), 767–771.
8. Fitzgerald, A.A., Powers, J.D., Ho, P.M., et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail 17 (2011), 664–669.
9. Krum, H., Schlaich, M., Whitbourn, R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373 (2009), 1275–1281.
10. Mahfoud, F., Luscher, T.F., Andersson, B., et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 34 (2013), 2149–2157.
11. Esler, M.D., Krum, H., Sobotka, P.A., et al., for the Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376 (2010), 1903–1909.
12. Bhatt, D.L., Kandzari, D.E., O'Neill, W.W., et al., for the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370 (2014), 1393–1401.
13. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101 (2000), 378–384.
14. Luchner, A., Burnett, J.C. Jr., Jougasaki, M., Hense, H.W., Riegger, G.A., Schunkert, H., Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 32 (1998), 1839–1844.
15. Davis, M.E., Richards, A.M., Nicholls, M.G., Yandle, T.G., Frampton, C.M., Troughton, R.W., Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 (2006), 977–985.
16. Hama, J., Nagata, S., Takenaka, T., et al. Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. Angiology 46 (1995), 511–516.
17. Nakaoka, H., Kitahara, Y., Amano, M., et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension 10 (1987), 221–225.
18. Yoshimoto, T., Naruse, M., Tanabe, A., et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology 139 (1998), 81–88.
19. Polhemus, D.J., Gao, J., Scarborough, A., et al. Radiofrequency renal denervation protects the ischemic heart via inhibition of GRK2 and increased nitric oxide signaling. Circ Res 119 (2016), 470–480.
20. Gao, J., Kerut, E.K., Smart, F., et al. Sympathoinhibitory effect of radiofrequency renal denervation in spontaneously hypertensive rats with established hypertension. Am J Hypertens 29 (2016), 1394–1401.
21. King, A.L., Polhemus, D.J., Bhushan, S., et al. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc Natl Acad Sci U S A 111 (2014), 3182–3187.
22. Carpenter, T.C., Stenmark, K.R., Hypoxia decreases lung neprilysin expression and increases pulmonary vascular leak. Am J Physiol Lung Cell Mol Physiol 281 (2001), L941–L948.
23. Watanabe, K., Ohta, Y., Inoue, M., et al. Bisoprolol improves survival in rats with heart failure. J Cardiovasc Pharmacol 38:Suppl 1 (2001), S55–S58.
24. Gu, J., Noe, A., Chandra, P., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50 (2010), 401–414.
25. von Lueder, T.G., Wang, B.H., Kompa, A.R., et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 8 (2015), 71–78.
26. Wang, T.J., The natriuretic peptides and fat metabolism. N Engl J Med 367 (2012), 377–378.
27. Nishikimi, T., Maeda, N., Matsuoka, H., The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69 (2006), 318–328.
28. Troughton, R.W., Frampton, C.M., Yandle, T.G., Espiner, E.A., Nicholls, M.G., Richards, A.M., Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000), 1126–1130.
29. Seino, Y., Ogawa, A., Yamashita, T., et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6 (2004), 295–300.
30. Vodovar, N., Seronde, M.F., Laribi, S., et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 35 (2014), 3434–3441.
31. Solomon, S.D., Zile, M., Pieske, B., et al., for the PARAMOUNT Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
32. McMurray, J.J., Packer, M., Desai, A.S., et al., for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
33. Packer, M., McMurray, J.J., Desai, A.S., et al., for the PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
34. Oliver, P.M., Fox, J.E., Kim, R., et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 94 (1997), 14730–14735.
35. Booz, G.W., Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system. Hypertension 45 (2005), 341–346.
36. Mohan, P., Brutsaert, D.L., Paulus, W.J., Sys, S.U., Myocardial contractile response to nitric oxide and cGMP. Circulation 93 (1996), 1223–1229.
37. Kapoun, A.M., Liang, F., O'Young, G., et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94 (2004), 453–461.
38. Motwani, J.G., Lang, C.C., Cramb, G., Struthers, A.D., Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension 25 (1995), 637–642.
39. Richards, A.M., Wittert, G.A., Crozier, I.G., et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertension 11 (1993), 407–416.
40. Waeber, B., Feihl, F., Blood-pressure reduction with LCZ696. Lancet 375 (2010), 1228–1229.
41. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92 (1995), 212–218.
42. Huebner, E.A., Strittmatter, S.M., Axon regeneration in the peripheral and central nervous systems. Results Probl Cell Differ 48 (2009), 339–351.
43. Krum, H., Schlaich, M.P., Sobotka, P.A., et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383 (2014), 622–629.